CTSO
Cytosorbents Corporation NASDAQ Listed Aug 8, 2006$0.43
+3.87%
vs $0.41
Mkt Cap $26.7M
52w Low $0.39
4.5% of range
52w High $1.29
50d MA $0.53
200d MA $0.69
P/E (TTM)
-2.3x
EV/EBITDA
—
P/B
4.5x
Debt/Equity
4.9x
ROE
-138.9%
P/FCF
-2.1x
RSI (14)
43.30
ATR (14)
$0.06
Beta
1.48
50d MA
$0.53
200d MA
$0.69
Avg Volume
225.0K
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
305 College Road East · Princeton, NJ 08540 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25, 2026 | AMC | -0.05 | -0.09 | -80.0% | 0.67 | -9.0% | -10.6% | -1.2% | -5.6% | +1.1% | -3.4% | — |
| Nov 13, 2025 | AMC | -0.06 | -0.04 | +33.3% | 0.67 | +2.2% | -0.8% | -0.6% | -5.3% | +2.8% | -2.6% | — |
| Aug 7, 2025 | AMC | -0.07 | -0.05 | +28.6% | 0.89 | +5.2% | +12.0% | +20.0% | -11.7% | +1.9% | +5.6% | — |
| May 14, 2025 | AMC | -0.08 | -0.06 | +25.0% | 0.81 | +4.1% | +3.3% | +7.8% | -5.5% | -1.2% | +3.5% | — |
| Mar 31, 2025 | AMC | -0.07 | -0.03 | +57.1% | 1.00 | +0.0% | +0.0% | +0.0% | -1.0% | -2.0% | +2.1% | — |
| Nov 7, 2024 | AMC | -0.07 | -0.08 | -14.3% | 0.90 | -1.4% | -18.1% | +25.7% | +4.3% | -4.5% | +2.6% | — |
| Aug 13, 2024 | AMC | -0.09 | -0.08 | +11.1% | 0.90 | -1.1% | +8.0% | +5.5% | +2.0% | +1.0% | +0.0% | — |
| May 9, 2024 | AMC | -0.12 | -0.12 | +0.0% | 0.81 | +2.5% | +12.3% | -8.2% | -0.4% | +1.1% | +3.0% | — |
| Mar 14, 2024 | AMC | -0.14 | -0.12 | +14.3% | 0.97 | -1.0% | -9.3% | +9.8% | -7.9% | -2.4% | -1.0% | — |
| Nov 9, 2023 | AMC | -0.12 | -0.21 | -75.0% | 1.26 | +14.3% | +0.8% | +1.6% | -0.8% | -8.6% | -6.0% | — |
| Aug 1, 2023 | AMC | -0.11 | -0.14 | -27.3% | 3.62 | -2.5% | -7.5% | -5.1% | +0.6% | -2.5% | -3.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26 | D. Boral Capital | Maintains | Buy → Buy | — | $0.67 | $0.61 | -9.0% | -10.6% | -1.2% | -5.6% | +1.1% | -3.4% |
| Jan 12 | D. Boral Capital | Maintains | Buy → Buy | — | $0.67 | $0.70 | +4.0% | +4.5% | +4.1% | -1.6% | -3.8% | +1.6% |
| Dec 16 | D. Boral Capital | Maintains | Buy → Buy | — | $0.63 | $0.64 | +2.4% | +2.2% | +0.5% | +0.3% | -1.3% | +20.3% |
| Nov 14 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $0.67 | $0.68 | +2.2% | -0.8% | -0.6% | -5.3% | +2.8% | -2.6% |
| Nov 14 | D. Boral Capital | Maintains | Buy → Buy | — | $0.67 | $0.68 | +2.2% | -0.8% | -0.6% | -5.3% | +2.8% | -2.6% |
| Sep 16 | D. Boral Capital | Maintains | Buy → Buy | — | $0.92 | $0.91 | -1.1% | -0.7% | -0.5% | +3.2% | +0.9% | +2.6% |
| Aug 20 | D. Boral Capital | Maintains | Buy → Buy | — | $1.08 | $1.01 | -6.5% | -17.2% | -5.6% | +8.2% | -0.7% | +2.6% |
| Aug 8 | D. Boral Capital | Maintains | Buy → Buy | — | $0.89 | $0.94 | +5.2% | +12.0% | +20.0% | -11.7% | +1.9% | +5.6% |
| Jul 21 | D. Boral Capital | Maintains | Buy → Buy | — | $1.03 | $1.02 | -1.0% | +1.0% | -3.8% | +2.0% | -2.0% | -5.6% |
| Jun 25 | D. Boral Capital | Maintains | Buy → Buy | — | $1.20 | $1.18 | -1.7% | +0.0% | -1.7% | +4.2% | +4.1% | +0.8% |
| May 15 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $0.81 | $0.84 | +4.1% | +3.3% | +7.8% | -5.5% | -1.2% | +3.5% |
| May 15 | D. Boral Capital | Maintains | Buy → Buy | — | $0.81 | $0.84 | +4.1% | +3.3% | +7.8% | -5.5% | -1.2% | +3.5% |
| May 2 | D. Boral Capital | Maintains | Buy → Buy | — | $1.01 | $0.92 | -8.9% | -6.9% | -3.4% | -2.0% | -0.8% | -1.5% |
| Apr 3 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $1.00 | $1.00 | +0.0% | -1.0% | -2.0% | +2.1% | -3.1% | -2.1% |
| Apr 1 | D. Boral Capital | Maintains | Buy → Buy | — | $1.00 | $1.00 | +0.0% | +0.0% | +0.0% | -1.0% | -2.0% | +2.1% |
| Feb 25 | D. Boral Capital | Maintains | Buy → Buy | — | $1.09 | $1.09 | +0.0% | +0.0% | +0.9% | -2.7% | -0.9% | -2.8% |
| Jan 13 | D. Boral Capital | Maintains | Buy → Buy | — | $0.94 | $0.94 | +0.2% | +12.0% | -1.0% | +3.8% | -3.7% | -1.0% |
| Jan 3 | D. Boral Capital | Maintains | Buy → Buy | — | $0.92 | $0.88 | -4.5% | +1.8% | +11.0% | -2.9% | -4.0% | -3.3% |
| Nov 12 | D. Boral Capital | Maintains | Buy → Buy | — | $0.93 | $0.95 | +2.2% | +4.3% | -4.5% | +2.6% | -5.8% | +3.9% |
| Nov 11 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $0.74 | $0.82 | +10.8% | +25.7% | +4.3% | -4.5% | +2.6% | -5.8% |
| Nov 8 | EF Hutton | Maintains | Buy → Buy | — | $0.90 | $0.89 | -1.4% | -18.1% | +25.7% | +4.3% | -4.5% | +2.6% |
| Nov 4 | EF Hutton | Maintains | Buy → Buy | — | $1.00 | $1.00 | -0.5% | -12.9% | -1.0% | +6.6% | -1.8% | -18.1% |
| Oct 22 | EF Hutton | Maintains | Buy → Buy | — | $1.05 | $1.06 | +1.0% | -1.0% | +1.0% | +0.0% | -1.0% | -2.9% |
| Oct 1 | EF Hutton | Maintains | Buy → Buy | — | $1.50 | $1.54 | +2.7% | -10.0% | -0.7% | -8.2% | -3.3% | -5.0% |
| Aug 14 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $0.90 | $0.89 | -1.1% | +8.0% | +5.5% | +2.0% | +1.0% | +0.0% |
| Aug 14 | EF Hutton | Maintains | Buy → Buy | — | $0.90 | $0.89 | -1.1% | +8.0% | +5.5% | +2.0% | +1.0% | +0.0% |
| May 15 | B. Riley Securities | Maintains | Buy → Buy | — | $0.83 | $0.83 | -0.2% | +1.1% | +3.0% | +11.7% | +1.2% | -4.0% |
| May 7 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $0.93 | $0.93 | +0.0% | +0.2% | -6.5% | -7.1% | +12.3% | -8.2% |
| Mar 15 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $0.97 | $0.96 | -1.0% | -9.3% | +9.8% | -7.9% | -2.4% | -1.0% |
| Dec 29 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $1.09 | $1.04 | -4.6% | +1.8% | -3.6% | -6.5% | -3.5% | -4.7% |
| Aug 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.62 | $3.53 | -2.5% | -7.5% | -5.1% | +0.6% | -2.5% | -3.8% |
| May 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.37 | $2.40 | +1.3% | +16.5% | +0.0% | +0.7% | +1.8% | +4.6% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.58 | $3.66 | +2.2% | +0.0% | -8.5% | +4.7% | -6.7% | +1.6% |
| Nov 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.95 | $1.60 | -17.9% | -15.9% | -5.5% | +1.9% | -7.6% | +2.1% |
| May 4 | B. Riley Securities | Maintains | Buy → Buy | — | $2.18 | $1.97 | -9.6% | -2.8% | -7.1% | -5.6% | +1.1% | +10.1% |
| May 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.18 | $1.97 | -9.6% | -2.8% | -7.1% | -5.6% | +1.1% | +10.1% |
| Sep 17 | Jefferies | Maintains | Buy → Buy | — | $8.31 | $8.48 | +2.0% | +5.1% | -0.7% | -3.8% | -1.8% | -4.9% |
| Sep 1 | SVB Leerink | Maintains | Outperform → Outperform | — | $8.44 | $8.69 | +3.0% | +0.6% | +0.1% | -9.3% | -3.2% | -1.2% |
| May 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.31 | $10.15 | +9.0% | +12.2% | -0.9% | +1.8% | +0.0% | -1.4% |
| May 6 | H.C. Wainwright | Maintains | Buy → Buy | — | $9.31 | $10.15 | +9.0% | +12.2% | -0.9% | +1.8% | +0.0% | -1.4% |
| May 6 | B. Riley Securities | Maintains | Buy → Buy | — | $9.31 | $10.15 | +9.0% | +12.2% | -0.9% | +1.8% | +0.0% | -1.4% |
| May 6 | B. Riley FBR | Maintains | Buy → Buy | — | $9.31 | $10.15 | +9.0% | +12.2% | -0.9% | +1.8% | +0.0% | -1.4% |
| Aug 8 | Maxim Group | Maintains | Buy → Buy | — | $4.75 | $5.25 | +10.5% | +4.2% | -6.1% | -3.2% | +2.2% | +3.3% |
| Jun 7 | TD Cowen | Maintains | Outperform → Outperform | — | $3.95 | $4.15 | +5.1% | +2.5% | -1.2% | -1.2% | -1.3% | -7.7% |
| Oct 26 | Aegis Capital | Maintains | Buy → Buy | — | $5.90 | $5.95 | +0.8% | +0.0% | -2.5% | +2.6% | +0.0% | -1.7% |
| Oct 7 | B. Riley FBR | Maintains | Buy → Buy | — | $5.63 | $5.87 | +4.3% | -0.9% | +6.6% | +0.8% | -5.0% | -2.6% |
| Mar 5 | MLV & Co. | Maintains | Buy → Buy | — | $10.87 | $11.09 | +2.0% | -0.6% | +5.6% | +2.5% | -4.6% | +1.9% |
| Feb 25 | WBB Securities | Maintains | Speculative Buy → Buy | — | $11.11 | $11.32 | +1.9% | +7.3% | -4.7% | +1.1% | -0.8% | -4.0% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | MARIANI PETER JOff | Chief Financial Officer | Buy | 100,000 | $0.44 | $44K | 638,113 | -8.07% | — |
| Jun 15, 2026 | Chan Phillip P.Dir/Off | Chief Executive Officer | Buy | 10,333 | $0.43 | $4K | 1,744,432 | +20.12% | +3.87% |
| Jun 12, 2026 | Chan Phillip P.Dir/Off | Chief Executive Officer | Buy | 251,136 | $0.40 | $100K | 1,734,099 | +20.12% | +3.87% |
8-K · 2.02
!! High
Cytosorbents Corporation -- 8-K 2.02: Earnings Results
May 13
8-K
Unknown — 8-K Filing
Cattso Group's stock price fell below Nasdaq's $1 minimum, risking delisting unless it recovers by March 2026, potentially destroying shareholder value if compliance isn't achieved.
Apr 2
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
CTSO's modest 4% revenue growth masks zero constant-currency expansion, while operating losses persist at $14.7M despite improvement, signaling continued profitability challenges ahead for investors.
Mar 25
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Avenir Corp | 5,215,776 | $3M | — | Mar 2026 |
| 2 | Skylands Capital, Llc | 1,854,515 | $1M | Reduced | Dec 2025 |
| 3 | Vanguard Capital Management Llc | 1,879,989 | $1M | New | Mar 2026 |
| 4 | Neuberger Berman Group Llc | 1,683,007 | $951K | Added | Mar 2026 |
| 5 | Cm Management, Llc | 1,476,500 | $944K | Added | Dec 2025 |
| 6 | Pathstone Holdings, Llc | 499,955 | $283K | — | Mar 2026 |
| 7 | Morgan Stanley | 232,960 | $149K | Added | Dec 2025 |
| 8 | Cibc Bancorp Usa Inc. | 172,649 | $98K | New | Mar 2026 |
| 9 | Ubs Group Ag | 115,200 | $65K | — | Mar 2026 |
| 10 | Raymond James Financial Inc | 107,751 | $61K | Reduced | Mar 2026 |
| 11 | Renaissance Technologies Llc | 100,720 | $57K | Added | Mar 2026 |
| 12 | Northern Trust Corp | 92,540 | $52K | — | Mar 2026 |
| 13 | Key Client Fiduciary Advisors, Llc | 78,457 | $44K | — | Mar 2026 |
| 14 | Waverly Advisors, Llc | 55,556 | $31K | — | Mar 2026 |
| 15 | Bank Of America Corp /de/ | 39,123 | $22K | Added | Mar 2026 |
| 16 | Susquehanna International Group, Llp | 29,945 | $17K | Reduced | Mar 2026 |
| 17 | Ep Wealth Advisors, Llc | 28,000 | $16K | — | Mar 2026 |
| 18 | First National Bank Of Omaha | 15,225 | $9K | — | Mar 2026 |
| 19 | Hrt Financial Lp | 14,113 | $7K | New | Mar 2026 |
| 20 | Citadel Advisors Llc | 10,799 | $6K | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 9
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 295,933 | $223K | Feb 2026 |
| 2 | iShares Micro-Cap ETF | 145,480 | $82K | Mar 2026 |
| 3 | Fidelity Total Market Index Fund | 94,319 | $71K | Feb 2026 |
| 4 | Fidelity Series Total Market Index Fund | 74,873 | $56K | Feb 2026 |
| 5 | Fidelity Nasdaq Composite Index Fund | 32,102 | $24K | Feb 2026 |
| 6 | Morgan Stanley Pathway Small-Mid Cap Equity ETF | 22,884 | $17K | Feb 2026 |
| 7 | Column Small Cap Select Fund | 6,741 | $5K | Feb 2026 |
| 8 | Column Small Cap Fund | 2,079 | $2K | Feb 2026 |
| 9 | Guggenheim Active Allocation Fund | 245 | $184 | Feb 2026 |
Valuation
Market Cap
$26.7M
Enterprise Value
$37.1M
P/E (TTM)
-2.28x
Forward P/E
—
PEG Ratio
0.07x
P/B
4.52x
P/S
0.72x
P/FCF
-2.13x
EV/EBITDA
—
Shares Out
62.2M
Financials (TTM)
Revenue
$37.2M
Net Income
-$11.8M
EBITDA
-$7.8M
Free Cash Flow
-$12.5M
Op Cash Flow
-$12.4M
EPS Basic
$-0.13
EPS Diluted
$-0.19
EPS Forward
$-0.17
Gross Margin
71.0%
Op Margin
-36.0%
Net Margin
-31.9%
Balance Sheet
Total Assets
$44.2M
Total Liab.
$38.3M
Total Equity
$5.9M
Cash
$6.2M
LT Debt
$16.7M
Book Value/Sh
$0.09
Debt/Equity
4.93x
Current Ratio
2.13
Quick Ratio
1.58
Returns & Growth
ROE
-138.9%
ROA
-18.6%
ROIC
-38.8%
Rev Growth YoY
+4.1%
EPS Growth YoY
+65.8%
Price Returns
2W
-9.4%
1M
-19.5%
3M
-34.8%
6M
-39.5%
12M
-41.6%
Technicals
52W High
$1.29
52W Low
$0.39
50d MA
$0.53
200d MA
$0.69
RSI (14)
43.30
ATR (14)
$0.06
Beta
1.48
Avg Volume
225K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 25, 2026 3:51am
· Source: financialmodelingprep.com